Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.1% - Should You Sell?

Key Points

• Eli Lilly and Company's stock fell by 1.1% on Tuesday, with shares trading between $798.71 and $799.85, significantly below its previous close of $808.96.
• Despite the recent dip, several analysts have maintained a positive outlook, with the company currently holding a consensus rating of "Moderate Buy" and a price target of $938.61.
• Institutional investors own approximately 82.53% of Eli Lilly's stock, with several firms increasing their positions in the second quarter, reflecting continued strong interest in the company's performance.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares traded down 1.1% on Tuesday . The stock traded as low as $798.71 and last traded at $799.85. 2,078,959 shares traded hands during trading, a decline of 49% from the average session volume of 4,039,116 shares. The stock had previously closed at $808.96.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Guggenheim reiterated a "buy" rating and set a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $938.61.

Eli Lilly and Company Stock Down 1.1%

The company has a market cap of $757.03 billion, a P/E ratio of 52.28, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business's fifty day moving average is $756.56 and its two-hundred day moving average is $766.20.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 earnings per share. The company's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company's stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently made changes to their positions in LLY. Precedent Wealth Partners LLC boosted its position in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after buying an additional 39 shares during the last quarter. Capital Advisors Inc. OK increased its stake in shares of Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock worth $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the second quarter worth $54,000. Duquesne Family Office LLC lifted its position in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares during the period. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company during the first quarter valued at $570,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.